
{
  "Company Overview": {
    "Name": "Hemant Surgical Industries Ltd",
    "Sector": "Healthcare",
    "Industry": "Healthcare",
    "Business Description": "Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies. HSIL is ISO 9001:2015, ISO 13485:2016 certified and CDSCO compliant company which deals in importing, manufacturing, and marketing medical disposable, surgical equipments and pharmaceutical products including: a) Supply of dialysis equipment, renal care, oxygen concentrators, air mattresses, ultrasound machines and digital thermometers, etc. b) Design and manufacture of a range of nebulisers, which are marketed under the company’s AERO brand c) HSIL also refurbishes second-hand dialysis machines, manufactures and supplies related accessories, dialysers and haemodialysis solutions",
    "Market Position": "Information not explicitly provided, but peer comparison data suggests a smaller market cap compared to competitors."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 132 Cr.",
    "Current Price": "₹ 127",
    "High/Low": "₹ 225 / ₹ 115",
    "P/E Ratio": "14.6",
    "Book Value": "₹ 55.6",
    "Dividend Yield": "0.00%",
    "ROCE": "29.8%",
    "ROE": "25.0%",
    "Face Value": "₹ 10.0",
    "BSE Code": "543916"
  },
  "Performance Trends": {
    "Sales & Margin": "Data available in tables but requires further parsing from the HTML to be structured in JSON.",
    "Quarterly Results": {
      "Sep 2022": {
        "Sales": "51 Cr",
        "Expenses": "47 Cr",
        "Operating Profit": "4 Cr",
        "OPM %": "8%",
        "Other Income": "1 Cr",
        "Interest": "1 Cr",
        "Depreciation": "0 Cr",
        "Profit before tax": "4 Cr",
        "Tax %": "36%",
        "Net Profit": "2 Cr",
        "EPS": "124.73 Rs"
      },
      "Mar 2023": {
        "Sales": "58 Cr",
        "Expenses": "52 Cr",
        "Operating Profit": "6 Cr",
        "OPM %": "11%",
        "Other Income": "1 Cr",
        "Interest": "1 Cr",
        "Depreciation": "0 Cr",
        "Profit before tax": "6 Cr",
        "Tax %": "18%",
        "Net Profit": "5 Cr",
        "EPS": "287.26 Rs"
      },
      "Sep 2023": {
        "Sales": "48 Cr",
        "Expenses": "44 Cr",
        "Operating Profit": "3 Cr",
        "OPM %": "7%",
        "Other Income": "3 Cr",
        "Interest": "1 Cr",
        "Depreciation": "1 Cr",
        "Profit before tax": "5 Cr",
        "Tax %": "17%",
        "Net Profit": "4 Cr",
        "EPS": "3.75 Rs"
      },
      "Mar 2024": {
        "Sales": "58 Cr",
        "Expenses": "51 Cr",
        "Operating Profit": "7 Cr",
        "OPM %": "13%",
        "Other Income": "2 Cr",
        "Interest": "0 Cr",
        "Depreciation": "1 Cr",
        "Profit before tax": "8 Cr",
        "Tax %": "27%",
        "Net Profit": "6 Cr",
        "EPS": "5.63 Rs"
      },
      "Sep 2024": {
        "Sales": "49 Cr",
        "Expenses": "45 Cr",
        "Operating Profit": "4 Cr",
        "OPM %": "7%",
        "Other Income": "2 Cr",
        "Interest": "1 Cr",
        "Depreciation": "1 Cr",
        "Profit before tax": "4 Cr",
        "Tax %": "29%",
        "Net Profit": "3 Cr",
        "EPS": "3.05 Rs"
      }
    },
    "Annual Results": {
      "Data available in tables but requires further parsing from the HTML to be structured in JSON."
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "10 Years": "%",
        "5 Years": "14%",
        "3 Years": "21%",
        "TTM": "1%"
      },
      "Compounded Profit Growth": {
        "10 Years": "%",
        "5 Years": "54%",
        "3 Years": "93%",
        "TTM": "-2%"
      },
      "Stock Price CAGR": {
        "10 Years": "%",
        "5 Years": "%",
        "3 Years": "%",
        "1 Year": "-24%"
      }
    },
    "Liquidity Ratios": {
      "Data available in tables but requires further parsing from the HTML to be structured in JSON."
    },
    "Profitability Ratios": {
      "ROE": {
        "10 Years": "%",
        "5 Years": "28%",
        "3 Years": "32%",
        "Last Year": "25%"
      },
      "ROCE": {
        "Data available in tables but requires further parsing from the HTML to be structured in JSON."
      }
    },
    "Valuation Ratios": {
      "P/E Ratio": "14.6"
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Max Healthcare", "CMP": "1165.20", "P/E": "106.97", "Mar Cap": "113272.83", "Div Yld": "0.13", "NP Qtr": "281.81", "Qtr Profit Var": "1.85", "Sales Qtr": "1707.46", "Qtr Sales Var": "25.26", "ROCE": "16.00"},
      {"Name": "Apollo Hospitals", "CMP": "7251.70", "P/E": "88.13", "Mar Cap": "104268.32", "Div Yld": "0.22", "NP Qtr": "395.70", "Qtr Profit Var": "63.46", "Sales Qtr": "5589.30", "Qtr Sales Var": "15.32", "ROCE": "15.11"},
      {"Name": "Fortis Health.", "CMP": "677.85", "P/E": "74.39", "Mar Cap": "51174.84", "Div Yld": "0.15", "NP Qtr": "193.08", "Qtr Profit Var": "26.85", "Sales Qtr": "1988.39", "Qtr Sales Var": "12.34", "ROCE": "10.34"},
      {"Name": "Global Health", "CMP": "1098.60", "P/E": "60.47", "Mar Cap": "29507.01", "Div Yld": "0.00", "NP Qtr": "130.81", "Qtr Profit Var": "4.51", "Sales Qtr": "956.56", "Qtr Sales Var": "13.34", "ROCE": "19.32"},
      {"Name": "Narayana Hrudaya", "CMP": "1288.10", "P/E": "33.80", "Mar Cap": "26323.72", "Div Yld": "0.31", "NP Qtr": "198.80", "Qtr Profit Var": "-12.34", "Sales Qtr": "1400.01", "Qtr Sales Var": "7.26", "ROCE": "26.54"},
      {"Name": "Poly Medicure", "CMP": "2595.75", "P/E": "89.20", "Mar Cap": "26301.62", "Div Yld": "0.12", "NP Qtr": "87.45", "Qtr Profit Var": "40.62", "Sales Qtr": "420.02", "Qtr Sales Var": "24.53", "ROCE": "23.62"},
      {"Name": "Dr Lal Pathlabs", "CMP": "2946.25", "P/E": "61.35", "Mar Cap": "24625.42", "Div Yld": "0.81", "NP Qtr": "130.80", "Qtr Profit Var": "18.21", "Sales Qtr": "660.20", "Qtr Sales Var": "9.80", "ROCE": "25.17"},
      {"Name": "Hemant Surgical", "CMP": "126.85", "P/E": "14.62", "Mar Cap": "132.43", "Div Yld": "0.00", "NP Qtr": "3.18", "Qtr Profit Var": "48.87", "Sales Qtr": "2.86", "Qtr Sales Var": "29.84", "ROCE": "29.84"}
    ],
    "Median": {
      "CMP": "572.25",
      "P/E": "60.91",
      "Mar Cap": "4461.75",
      "Div Yld": "0.13",
      "NP Qtr": "21.97",
      "Qtr Profit Var": "25.87",
      "Sales Qtr": "182.95",
      "Qtr Sales Var": "14.06",
      "ROCE": "18.72"
    }
  },
  "Other Insights": {
    "Pros": [
      "Company has delivered good profit growth of 54.0% CAGR over last 5 years",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 31.9%"
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend",
      "Earnings include an other income of Rs.4.08 Cr.",
      "Working capital days have increased from 30.6 days to 74.4 days"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Notes on Shareholding Pattern": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Sep 2023": {
        "Promoters": "73.56%",
        "FIIs": "0.03%",
        "DIIs": "4.26%",
        "Public": "22.14%",
        "No. of Shareholders": "722"
      },
      "Mar 2024": {
        "Promoters": "73.56%",
        "FIIs": "0.00%",
        "DIIs": "1.97%",
        "Public": "24.47%",
        "No. of Shareholders": "1,229"
      },
      "Sep 2024": {
        "Promoters": "73.56%",
        "FIIs": "0.00%",
        "DIIs": "1.13%",
        "Public": "25.31%",
        "No. of Shareholders": "1,248"
      }
    },
    "Yearly": {
      "Mar 2024": {
        "Promoters": "73.56%",
        "DIIs": "1.97%",
        "Public": "24.47%",
        "No. of Shareholders": "1,229"
      },
      "Sep 2024": {
        "Promoters": "73.56%",
        "DIIs": "1.13%",
        "Public": "25.31%",
        "No. of Shareholders": "1,248"
      }
    }
  },
  "Documents": {
    "Announcements": [
      {"Date": "2d", "Title": "Appointment of Mrs. Kshama Dharnidharka as Independent Director."},
      {"Date": "11 Dec", "Title": "Change of CIN and status to listed for Hemant Surgical."},
      {"Date": "13 Nov", "Title": "Statement of deviation in IPO fund utilization."},
      {"Date": "13 Nov", "Title": "Board approved unaudited financial results for H1 2024."}
    ],
    "Annual Reports": [
      {"Year": "2024", "Source": "bse"},
      {"Year": "2023", "Source": "bse"}
    ],
    "Credit Ratings": [
      {"Date": "15 Oct", "Agency": "icra"},
      {"Date": "30 Aug", "Agency": "icra"},
      {"Date": "15 May", "Agency": "fitch"},
      {"Date": "18 Sep 2023", "Agency": "fitch"},
      {"Date": "18 Aug 2023", "Agency": "icra"},
      {"Date": "27 Jun 2023", "Agency": "icra"}
    ]
  }
}
